Stages
115 articles
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Precision Medicine from the Get-Go for Pancreatic Cancer
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Tumor Biology Matters
Dr. Lynn Matrisian of PanCAN, explains that molecular profiling of a pancreatic cancer patient’s tumor can show which treatment will work best.
New Liquid Biopsy Shows Promise for Early Detection
Dr. Ajay Goel has a new approach to a liquid biopsy early detection test for pancreatic cancer. So far, the results are very impressive.
Using AI to Create a Better Test to Predict Pancreatic Cancer Progression
Dr. Dan Theodorescu is using AI to isolate more effective biomarkers than the CA 19-9 test to track pancreatic cancer progression.
New Study Shows Benefit of Chemotherapy after Surgery
Should you have adjuvant chemotherapy–treatment after pancreatic cancer surgery? Dr. Marco Del Chiaro explains that the evidence says “yes.”
New Prospective Clinical Study of Blood-Based Early Detection Test
Dr. Rosalie Sears is working with Biological Dynamics to test a new early detection blood assay and platform for pancreatic cancer screening.
Surveillance Improves Outcomes for High-Risk Patients
Dr. Michael Goggins provides results for the CAPS5 pancreatic cancer surveillance and screening study for patients at high risk.
Finding More Targets for Pancreatic Cancer Treatment
Dr. Noelle LoConte discusses a clinical trial for cancer patients, including pancreatic cancer patients, that have an NRG1 gene fusion.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
New Cancer Stem Cell Pathway Drug May Change Standard of Care
Dr. Tanios Bekaii-Saab is testing a new drug that works on pancreatic cancer stem cells to make chemotherapy more effective.
Precision Promise Places Patients at Center of Research
Dr. Diane Simeone explains the different approach to pancreatic cancer clinical trials taken by the Precision Promise program.
Immunotherapy for Pancreatic Neuroendocrine Tumors
A clinical trial combines the immunotherapy drug pembrolizumab with lanreotide, a drug typically used to treat pancreatic neuroendocrine tumors.